Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab DDI Study in UC/CD
NCT04254783Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of risankizumab in ulcerative colitis (UC) and Crohn's disease, sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Midazolam up to 71 Days, Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam up to 71 Days and 13 more. Started May 2020; status: completed.
02
Drugs
risankizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04254783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04254783.